Global Peptide-Radionuclide Conjugates (PRCs) Market Growth 2026-2032
The global Peptide-Radionuclide Conjugates (PRCs) market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Peptide-Radionuclide Conjugates (PRCs) are advanced therapeutic and diagnostic tools used in nuclear medicine that combine a peptide, which specifically binds to certain receptors on cancer cells, with a radionuclide, which emits radiation. The peptide component targets and binds to receptors that are overexpressed on the surface of tumor cells, such as somatostatin receptors in neuroendocrine tumors. The attached radionuclide then emits either beta or alpha particles, which deliver targeted radiation directly to the cancer cells, leading to their destruction. This combination allows for highly specific treatment of cancerous tissues while minimizing damage to surrounding healthy tissues, making PRCs valuable in both imaging (for diagnosis) and therapy (for treatment).
The market for Peptide-Radionuclide Conjugates (PRCs) is experiencing significant growth, driven by advances in targeted cancer therapies and diagnostics. The increasing prevalence of cancers that express specific receptors, such as neuroendocrine tumors, has led to a rising demand for PRCs. These conjugates offer precise targeting and localized radiation treatment, making them a valuable tool in oncology. Additionally, the approval and commercialization of PRCs like ^177Lu-DOTATATE (Lutathera) have spurred interest and investment in this niche market, contributing to its expansion.
Recent trends highlight substantial progress in both the development and application of PRCs. Ongoing research and clinical trials are focused on improving the efficacy, safety, and specificity of these therapies. Innovations include the development of new peptides with enhanced receptor binding properties and novel radionuclides that may offer better therapeutic outcomes or reduced side effects. This research is not only expanding the indications for existing PRCs but also paving the way for new therapeutic and diagnostic options, further driving market growth.
Despite the positive outlook, the PRC market faces several challenges. High costs associated with the development and manufacturing of PRCs, along with the complexity of their production, can limit market accessibility and adoption. Additionally, competition from other targeted therapies and advancements in immunotherapy may influence market dynamics. Nevertheless, the continuous innovation in PRC technologies and the increasing number of clinical indications are likely to sustain market growth, offering promising prospects for both existing and emerging products in the sector.
LP Information, Inc. (LPI) ' newest research report, the “Peptide-Radionuclide Conjugates (PRCs) Industry Forecast” looks at past sales and reviews total world Peptide-Radionuclide Conjugates (PRCs) sales in 2025, providing a comprehensive analysis by region and market sector of projected Peptide-Radionuclide Conjugates (PRCs) sales for 2026 through 2032. With Peptide-Radionuclide Conjugates (PRCs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide-Radionuclide Conjugates (PRCs) industry.
This Insight Report provides a comprehensive analysis of the global Peptide-Radionuclide Conjugates (PRCs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Peptide-Radionuclide Conjugates (PRCs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Peptide-Radionuclide Conjugates (PRCs) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide-Radionuclide Conjugates (PRCs) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide-Radionuclide Conjugates (PRCs).
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide-Radionuclide Conjugates (PRCs) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Peptide-Radionuclide Conjugates (PRCs) are advanced therapeutic and diagnostic tools used in nuclear medicine that combine a peptide, which specifically binds to certain receptors on cancer cells, with a radionuclide, which emits radiation. The peptide component targets and binds to receptors that are overexpressed on the surface of tumor cells, such as somatostatin receptors in neuroendocrine tumors. The attached radionuclide then emits either beta or alpha particles, which deliver targeted radiation directly to the cancer cells, leading to their destruction. This combination allows for highly specific treatment of cancerous tissues while minimizing damage to surrounding healthy tissues, making PRCs valuable in both imaging (for diagnosis) and therapy (for treatment).
The market for Peptide-Radionuclide Conjugates (PRCs) is experiencing significant growth, driven by advances in targeted cancer therapies and diagnostics. The increasing prevalence of cancers that express specific receptors, such as neuroendocrine tumors, has led to a rising demand for PRCs. These conjugates offer precise targeting and localized radiation treatment, making them a valuable tool in oncology. Additionally, the approval and commercialization of PRCs like ^177Lu-DOTATATE (Lutathera) have spurred interest and investment in this niche market, contributing to its expansion.
Recent trends highlight substantial progress in both the development and application of PRCs. Ongoing research and clinical trials are focused on improving the efficacy, safety, and specificity of these therapies. Innovations include the development of new peptides with enhanced receptor binding properties and novel radionuclides that may offer better therapeutic outcomes or reduced side effects. This research is not only expanding the indications for existing PRCs but also paving the way for new therapeutic and diagnostic options, further driving market growth.
Despite the positive outlook, the PRC market faces several challenges. High costs associated with the development and manufacturing of PRCs, along with the complexity of their production, can limit market accessibility and adoption. Additionally, competition from other targeted therapies and advancements in immunotherapy may influence market dynamics. Nevertheless, the continuous innovation in PRC technologies and the increasing number of clinical indications are likely to sustain market growth, offering promising prospects for both existing and emerging products in the sector.
LP Information, Inc. (LPI) ' newest research report, the “Peptide-Radionuclide Conjugates (PRCs) Industry Forecast” looks at past sales and reviews total world Peptide-Radionuclide Conjugates (PRCs) sales in 2025, providing a comprehensive analysis by region and market sector of projected Peptide-Radionuclide Conjugates (PRCs) sales for 2026 through 2032. With Peptide-Radionuclide Conjugates (PRCs) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide-Radionuclide Conjugates (PRCs) industry.
This Insight Report provides a comprehensive analysis of the global Peptide-Radionuclide Conjugates (PRCs) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Peptide-Radionuclide Conjugates (PRCs) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Peptide-Radionuclide Conjugates (PRCs) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide-Radionuclide Conjugates (PRCs) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide-Radionuclide Conjugates (PRCs).
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide-Radionuclide Conjugates (PRCs) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Diagnostic PRCs
- Therapeutic PRCs
- Prostate Cancer
- Neuroendocrine Tumors
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novartis
- RadioMedix
- Curium Pharma
- Telix Pharmaceutical
- ITM Radiopharma
- Grand Pharmaceutical
- What is the 10-year outlook for the global Peptide-Radionuclide Conjugates (PRCs) market?
- What factors are driving Peptide-Radionuclide Conjugates (PRCs) market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Peptide-Radionuclide Conjugates (PRCs) market opportunities vary by end market size?
- How does Peptide-Radionuclide Conjugates (PRCs) break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Peptide-Radionuclide Conjugates (PRCs) by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Peptide-Radionuclide Conjugates (PRCs) by Country/Region, 2021, 2025 & 2032
2.2 Peptide-Radionuclide Conjugates (PRCs) Segment by Type
2.2.1 Diagnostic PRCs
2.2.2 Therapeutic PRCs
2.2.3 Peptide-Radionuclide Conjugates (PRCs) Sales by Type
2.2.3.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2026)
2.2.3.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Peptide-Radionuclide Conjugates (PRCs) Sale Price by Type (2021-2026)
2.3 Peptide-Radionuclide Conjugates (PRCs) Segment by Application
2.3.1 Prostate Cancer
2.3.2 Neuroendocrine Tumors
2.3.3 Other
2.3.4 Peptide-Radionuclide Conjugates (PRCs) Sales by Application
2.3.4.1 Global Peptide-Radionuclide Conjugates (PRCs) Sale Market Share by Application (2021-2026)
2.3.4.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Peptide-Radionuclide Conjugates (PRCs) Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Peptide-Radionuclide Conjugates (PRCs) Breakdown Data by Company
3.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Annual Sales by Company (2021-2026)
3.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Company (2021-2026)
3.2 Global Peptide-Radionuclide Conjugates (PRCs) Annual Revenue by Company (2021-2026)
3.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Company (2021-2026)
3.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Company (2021-2026)
3.3 Global Peptide-Radionuclide Conjugates (PRCs) Sale Price by Company
3.4 Key Manufacturers Peptide-Radionuclide Conjugates (PRCs) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Peptide-Radionuclide Conjugates (PRCs) Product Location Distribution
3.4.2 Players Peptide-Radionuclide Conjugates (PRCs) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PEPTIDE-RADIONUCLIDE CONJUGATES (PRCS) BY GEOGRAPHIC REGION
4.1 World Historic Peptide-Radionuclide Conjugates (PRCs) Market Size by Geographic Region (2021-2026)
4.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Peptide-Radionuclide Conjugates (PRCs) Market Size by Country/Region (2021-2026)
4.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Annual Sales by Country/Region (2021-2026)
4.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Peptide-Radionuclide Conjugates (PRCs) Sales Growth
4.4 APAC Peptide-Radionuclide Conjugates (PRCs) Sales Growth
4.5 Europe Peptide-Radionuclide Conjugates (PRCs) Sales Growth
4.6 Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales Growth
5 AMERICAS
5.1 Americas Peptide-Radionuclide Conjugates (PRCs) Sales by Country
5.1.1 Americas Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026)
5.1.2 Americas Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021-2026)
5.2 Americas Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026)
5.3 Americas Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide-Radionuclide Conjugates (PRCs) Sales by Region
6.1.1 APAC Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2021-2026)
6.1.2 APAC Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (2021-2026)
6.2 APAC Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026)
6.3 APAC Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Peptide-Radionuclide Conjugates (PRCs) by Country
7.1.1 Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026)
7.1.2 Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021-2026)
7.2 Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026)
7.3 Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) by Country
8.1.1 Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026)
8.1.2 Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021-2026)
8.2 Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026)
8.3 Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Peptide-Radionuclide Conjugates (PRCs)
10.3 Manufacturing Process Analysis of Peptide-Radionuclide Conjugates (PRCs)
10.4 Industry Chain Structure of Peptide-Radionuclide Conjugates (PRCs)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Peptide-Radionuclide Conjugates (PRCs) Distributors
11.3 Peptide-Radionuclide Conjugates (PRCs) Customer
12 WORLD FORECAST REVIEW FOR PEPTIDE-RADIONUCLIDE CONJUGATES (PRCS) BY GEOGRAPHIC REGION
12.1 Global Peptide-Radionuclide Conjugates (PRCs) Market Size Forecast by Region
12.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Forecast by Region (2027-2032)
12.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Peptide-Radionuclide Conjugates (PRCs) Forecast by Type (2027-2032)
12.7 Global Peptide-Radionuclide Conjugates (PRCs) Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
13.1.3 Novartis Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 RadioMedix
13.2.1 RadioMedix Company Information
13.2.2 RadioMedix Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
13.2.3 RadioMedix Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 RadioMedix Main Business Overview
13.2.5 RadioMedix Latest Developments
13.3 Curium Pharma
13.3.1 Curium Pharma Company Information
13.3.2 Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
13.3.3 Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Curium Pharma Main Business Overview
13.3.5 Curium Pharma Latest Developments
13.4 Telix Pharmaceutical
13.4.1 Telix Pharmaceutical Company Information
13.4.2 Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
13.4.3 Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Telix Pharmaceutical Main Business Overview
13.4.5 Telix Pharmaceutical Latest Developments
13.5 ITM Radiopharma
13.5.1 ITM Radiopharma Company Information
13.5.2 ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
13.5.3 ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 ITM Radiopharma Main Business Overview
13.5.5 ITM Radiopharma Latest Developments
13.6 Grand Pharmaceutical
13.6.1 Grand Pharmaceutical Company Information
13.6.2 Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
13.6.3 Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Grand Pharmaceutical Main Business Overview
13.6.5 Grand Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Peptide-Radionuclide Conjugates (PRCs) by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Peptide-Radionuclide Conjugates (PRCs) by Country/Region, 2021, 2025 & 2032
2.2 Peptide-Radionuclide Conjugates (PRCs) Segment by Type
2.2.1 Diagnostic PRCs
2.2.2 Therapeutic PRCs
2.2.3 Peptide-Radionuclide Conjugates (PRCs) Sales by Type
2.2.3.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2026)
2.2.3.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Peptide-Radionuclide Conjugates (PRCs) Sale Price by Type (2021-2026)
2.3 Peptide-Radionuclide Conjugates (PRCs) Segment by Application
2.3.1 Prostate Cancer
2.3.2 Neuroendocrine Tumors
2.3.3 Other
2.3.4 Peptide-Radionuclide Conjugates (PRCs) Sales by Application
2.3.4.1 Global Peptide-Radionuclide Conjugates (PRCs) Sale Market Share by Application (2021-2026)
2.3.4.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Peptide-Radionuclide Conjugates (PRCs) Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Peptide-Radionuclide Conjugates (PRCs) Breakdown Data by Company
3.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Annual Sales by Company (2021-2026)
3.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Company (2021-2026)
3.2 Global Peptide-Radionuclide Conjugates (PRCs) Annual Revenue by Company (2021-2026)
3.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Company (2021-2026)
3.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Company (2021-2026)
3.3 Global Peptide-Radionuclide Conjugates (PRCs) Sale Price by Company
3.4 Key Manufacturers Peptide-Radionuclide Conjugates (PRCs) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Peptide-Radionuclide Conjugates (PRCs) Product Location Distribution
3.4.2 Players Peptide-Radionuclide Conjugates (PRCs) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PEPTIDE-RADIONUCLIDE CONJUGATES (PRCS) BY GEOGRAPHIC REGION
4.1 World Historic Peptide-Radionuclide Conjugates (PRCs) Market Size by Geographic Region (2021-2026)
4.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Peptide-Radionuclide Conjugates (PRCs) Market Size by Country/Region (2021-2026)
4.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Annual Sales by Country/Region (2021-2026)
4.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Peptide-Radionuclide Conjugates (PRCs) Sales Growth
4.4 APAC Peptide-Radionuclide Conjugates (PRCs) Sales Growth
4.5 Europe Peptide-Radionuclide Conjugates (PRCs) Sales Growth
4.6 Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales Growth
5 AMERICAS
5.1 Americas Peptide-Radionuclide Conjugates (PRCs) Sales by Country
5.1.1 Americas Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026)
5.1.2 Americas Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021-2026)
5.2 Americas Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026)
5.3 Americas Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide-Radionuclide Conjugates (PRCs) Sales by Region
6.1.1 APAC Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2021-2026)
6.1.2 APAC Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (2021-2026)
6.2 APAC Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026)
6.3 APAC Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Peptide-Radionuclide Conjugates (PRCs) by Country
7.1.1 Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026)
7.1.2 Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021-2026)
7.2 Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026)
7.3 Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) by Country
8.1.1 Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026)
8.1.2 Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021-2026)
8.2 Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026)
8.3 Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Peptide-Radionuclide Conjugates (PRCs)
10.3 Manufacturing Process Analysis of Peptide-Radionuclide Conjugates (PRCs)
10.4 Industry Chain Structure of Peptide-Radionuclide Conjugates (PRCs)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Peptide-Radionuclide Conjugates (PRCs) Distributors
11.3 Peptide-Radionuclide Conjugates (PRCs) Customer
12 WORLD FORECAST REVIEW FOR PEPTIDE-RADIONUCLIDE CONJUGATES (PRCS) BY GEOGRAPHIC REGION
12.1 Global Peptide-Radionuclide Conjugates (PRCs) Market Size Forecast by Region
12.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Forecast by Region (2027-2032)
12.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Peptide-Radionuclide Conjugates (PRCs) Forecast by Type (2027-2032)
12.7 Global Peptide-Radionuclide Conjugates (PRCs) Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Novartis
13.1.1 Novartis Company Information
13.1.2 Novartis Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
13.1.3 Novartis Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Novartis Main Business Overview
13.1.5 Novartis Latest Developments
13.2 RadioMedix
13.2.1 RadioMedix Company Information
13.2.2 RadioMedix Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
13.2.3 RadioMedix Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 RadioMedix Main Business Overview
13.2.5 RadioMedix Latest Developments
13.3 Curium Pharma
13.3.1 Curium Pharma Company Information
13.3.2 Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
13.3.3 Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Curium Pharma Main Business Overview
13.3.5 Curium Pharma Latest Developments
13.4 Telix Pharmaceutical
13.4.1 Telix Pharmaceutical Company Information
13.4.2 Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
13.4.3 Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Telix Pharmaceutical Main Business Overview
13.4.5 Telix Pharmaceutical Latest Developments
13.5 ITM Radiopharma
13.5.1 ITM Radiopharma Company Information
13.5.2 ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
13.5.3 ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 ITM Radiopharma Main Business Overview
13.5.5 ITM Radiopharma Latest Developments
13.6 Grand Pharmaceutical
13.6.1 Grand Pharmaceutical Company Information
13.6.2 Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
13.6.3 Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Grand Pharmaceutical Main Business Overview
13.6.5 Grand Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Peptide-Radionuclide Conjugates (PRCs) Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Peptide-Radionuclide Conjugates (PRCs) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Diagnostic PRCs
Table 4. Major Players of Therapeutic PRCs
Table 5. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units)
Table 6. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2026)
Table 7. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2026) & ($ million)
Table 8. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2021-2026)
Table 9. Global Peptide-Radionuclide Conjugates (PRCs) Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Peptide-Radionuclide Conjugates (PRCs) Sale by Application (2021-2026) & (K Units)
Table 11. Global Peptide-Radionuclide Conjugates (PRCs) Sale Market Share by Application (2021-2026)
Table 12. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2026) & ($ million)
Table 13. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application (2021-2026)
Table 14. Global Peptide-Radionuclide Conjugates (PRCs) Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Company (2021-2026) & (K Units)
Table 16. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Company (2021-2026)
Table 17. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Company (2021-2026)
Table 19. Global Peptide-Radionuclide Conjugates (PRCs) Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Peptide-Radionuclide Conjugates (PRCs) Producing Area Distribution and Sales Area
Table 21. Players Peptide-Radionuclide Conjugates (PRCs) Products Offered
Table 22. Peptide-Radionuclide Conjugates (PRCs) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share Geographic Region (2021-2026)
Table 27. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country/Region (2021-2026)
Table 31. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026) & (K Units)
Table 34. Americas Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country (2021-2026)
Table 35. Americas Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units)
Table 37. Americas Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026) & (K Units)
Table 38. APAC Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2021-2026) & (K Units)
Table 39. APAC Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Region (2021-2026)
Table 40. APAC Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units)
Table 42. APAC Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026) & (K Units)
Table 43. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026) & (K Units)
Table 44. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units)
Table 46. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Peptide-Radionuclide Conjugates (PRCs)
Table 52. Key Market Challenges & Risks of Peptide-Radionuclide Conjugates (PRCs)
Table 53. Key Industry Trends of Peptide-Radionuclide Conjugates (PRCs)
Table 54. Peptide-Radionuclide Conjugates (PRCs) Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Peptide-Radionuclide Conjugates (PRCs) Distributors List
Table 57. Peptide-Radionuclide Conjugates (PRCs) Customer List
Table 58. Global Peptide-Radionuclide Conjugates (PRCs) Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Peptide-Radionuclide Conjugates (PRCs) Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Peptide-Radionuclide Conjugates (PRCs) Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Peptide-Radionuclide Conjugates (PRCs) Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Peptide-Radionuclide Conjugates (PRCs) Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Peptide-Radionuclide Conjugates (PRCs) Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Peptide-Radionuclide Conjugates (PRCs) Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Novartis Basic Information, Peptide-Radionuclide Conjugates (PRCs) Manufacturing Base, Sales Area and Its Competitors
Table 73. Novartis Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
Table 74. Novartis Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Novartis Main Business
Table 76. Novartis Latest Developments
Table 77. RadioMedix Basic Information, Peptide-Radionuclide Conjugates (PRCs) Manufacturing Base, Sales Area and Its Competitors
Table 78. RadioMedix Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
Table 79. RadioMedix Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. RadioMedix Main Business
Table 81. RadioMedix Latest Developments
Table 82. Curium Pharma Basic Information, Peptide-Radionuclide Conjugates (PRCs) Manufacturing Base, Sales Area and Its Competitors
Table 83. Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
Table 84. Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Curium Pharma Main Business
Table 86. Curium Pharma Latest Developments
Table 87. Telix Pharmaceutical Basic Information, Peptide-Radionuclide Conjugates (PRCs) Manufacturing Base, Sales Area and Its Competitors
Table 88. Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
Table 89. Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Telix Pharmaceutical Main Business
Table 91. Telix Pharmaceutical Latest Developments
Table 92. ITM Radiopharma Basic Information, Peptide-Radionuclide Conjugates (PRCs) Manufacturing Base, Sales Area and Its Competitors
Table 93. ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
Table 94. ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. ITM Radiopharma Main Business
Table 96. ITM Radiopharma Latest Developments
Table 97. Grand Pharmaceutical Basic Information, Peptide-Radionuclide Conjugates (PRCs) Manufacturing Base, Sales Area and Its Competitors
Table 98. Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
Table 99. Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Grand Pharmaceutical Main Business
Table 101. Grand Pharmaceutical Latest Developments
Table 1. Peptide-Radionuclide Conjugates (PRCs) Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Peptide-Radionuclide Conjugates (PRCs) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Diagnostic PRCs
Table 4. Major Players of Therapeutic PRCs
Table 5. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units)
Table 6. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2026)
Table 7. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2026) & ($ million)
Table 8. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2021-2026)
Table 9. Global Peptide-Radionuclide Conjugates (PRCs) Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Global Peptide-Radionuclide Conjugates (PRCs) Sale by Application (2021-2026) & (K Units)
Table 11. Global Peptide-Radionuclide Conjugates (PRCs) Sale Market Share by Application (2021-2026)
Table 12. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2026) & ($ million)
Table 13. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application (2021-2026)
Table 14. Global Peptide-Radionuclide Conjugates (PRCs) Sale Price by Application (2021-2026) & (US$/Unit)
Table 15. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Company (2021-2026) & (K Units)
Table 16. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Company (2021-2026)
Table 17. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Company (2021-2026) & ($ millions)
Table 18. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Company (2021-2026)
Table 19. Global Peptide-Radionuclide Conjugates (PRCs) Sale Price by Company (2021-2026) & (US$/Unit)
Table 20. Key Manufacturers Peptide-Radionuclide Conjugates (PRCs) Producing Area Distribution and Sales Area
Table 21. Players Peptide-Radionuclide Conjugates (PRCs) Products Offered
Table 22. Peptide-Radionuclide Conjugates (PRCs) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 23. New Products and Potential Entrants
Table 24. Market M&A Activity & Strategy
Table 25. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Geographic Region (2021-2026) & (K Units)
Table 26. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share Geographic Region (2021-2026)
Table 27. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Geographic Region (2021-2026) & ($ millions)
Table 28. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Geographic Region (2021-2026)
Table 29. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Country/Region (2021-2026) & (K Units)
Table 30. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country/Region (2021-2026)
Table 31. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Country/Region (2021-2026) & ($ millions)
Table 32. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Country/Region (2021-2026)
Table 33. Americas Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026) & (K Units)
Table 34. Americas Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country (2021-2026)
Table 35. Americas Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021-2026) & ($ millions)
Table 36. Americas Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units)
Table 37. Americas Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026) & (K Units)
Table 38. APAC Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2021-2026) & (K Units)
Table 39. APAC Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Region (2021-2026)
Table 40. APAC Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (2021-2026) & ($ millions)
Table 41. APAC Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units)
Table 42. APAC Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026) & (K Units)
Table 43. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026) & (K Units)
Table 44. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021-2026) & ($ millions)
Table 45. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units)
Table 46. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026) & (K Units)
Table 47. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026) & (K Units)
Table 48. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Country (2021-2026)
Table 49. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units)
Table 50. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026) & (K Units)
Table 51. Key Market Drivers & Growth Opportunities of Peptide-Radionuclide Conjugates (PRCs)
Table 52. Key Market Challenges & Risks of Peptide-Radionuclide Conjugates (PRCs)
Table 53. Key Industry Trends of Peptide-Radionuclide Conjugates (PRCs)
Table 54. Peptide-Radionuclide Conjugates (PRCs) Raw Material
Table 55. Key Suppliers of Raw Materials
Table 56. Peptide-Radionuclide Conjugates (PRCs) Distributors List
Table 57. Peptide-Radionuclide Conjugates (PRCs) Customer List
Table 58. Global Peptide-Radionuclide Conjugates (PRCs) Sales Forecast by Region (2027-2032) & (K Units)
Table 59. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Forecast by Region (2027-2032) & ($ millions)
Table 60. Americas Peptide-Radionuclide Conjugates (PRCs) Sales Forecast by Country (2027-2032) & (K Units)
Table 61. Americas Peptide-Radionuclide Conjugates (PRCs) Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 62. APAC Peptide-Radionuclide Conjugates (PRCs) Sales Forecast by Region (2027-2032) & (K Units)
Table 63. APAC Peptide-Radionuclide Conjugates (PRCs) Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 64. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Forecast by Country (2027-2032) & (K Units)
Table 65. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 66. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Global Peptide-Radionuclide Conjugates (PRCs) Sales Forecast by Type (2027-2032) & (K Units)
Table 69. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Forecast by Type (2027-2032) & ($ millions)
Table 70. Global Peptide-Radionuclide Conjugates (PRCs) Sales Forecast by Application (2027-2032) & (K Units)
Table 71. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Forecast by Application (2027-2032) & ($ millions)
Table 72. Novartis Basic Information, Peptide-Radionuclide Conjugates (PRCs) Manufacturing Base, Sales Area and Its Competitors
Table 73. Novartis Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
Table 74. Novartis Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 75. Novartis Main Business
Table 76. Novartis Latest Developments
Table 77. RadioMedix Basic Information, Peptide-Radionuclide Conjugates (PRCs) Manufacturing Base, Sales Area and Its Competitors
Table 78. RadioMedix Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
Table 79. RadioMedix Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. RadioMedix Main Business
Table 81. RadioMedix Latest Developments
Table 82. Curium Pharma Basic Information, Peptide-Radionuclide Conjugates (PRCs) Manufacturing Base, Sales Area and Its Competitors
Table 83. Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
Table 84. Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 85. Curium Pharma Main Business
Table 86. Curium Pharma Latest Developments
Table 87. Telix Pharmaceutical Basic Information, Peptide-Radionuclide Conjugates (PRCs) Manufacturing Base, Sales Area and Its Competitors
Table 88. Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
Table 89. Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 90. Telix Pharmaceutical Main Business
Table 91. Telix Pharmaceutical Latest Developments
Table 92. ITM Radiopharma Basic Information, Peptide-Radionuclide Conjugates (PRCs) Manufacturing Base, Sales Area and Its Competitors
Table 93. ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
Table 94. ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 95. ITM Radiopharma Main Business
Table 96. ITM Radiopharma Latest Developments
Table 97. Grand Pharmaceutical Basic Information, Peptide-Radionuclide Conjugates (PRCs) Manufacturing Base, Sales Area and Its Competitors
Table 98. Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolios and Specifications
Table 99. Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 100. Grand Pharmaceutical Main Business
Table 101. Grand Pharmaceutical Latest Developments
LIST OF FIGURES
Figure 1. Picture of Peptide-Radionuclide Conjugates (PRCs)
Figure 2. Peptide-Radionuclide Conjugates (PRCs) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Peptide-Radionuclide Conjugates (PRCs) Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Peptide-Radionuclide Conjugates (PRCs) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country/Region (2025)
Figure 10. Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Diagnostic PRCs
Figure 12. Product Picture of Therapeutic PRCs
Figure 13. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type in 2026
Figure 14. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2021-2026)
Figure 15. Peptide-Radionuclide Conjugates (PRCs) Consumed in Prostate Cancer
Figure 16. Global Peptide-Radionuclide Conjugates (PRCs) Market: Prostate Cancer (2021-2026) & (K Units)
Figure 17. Peptide-Radionuclide Conjugates (PRCs) Consumed in Neuroendocrine Tumors
Figure 18. Global Peptide-Radionuclide Conjugates (PRCs) Market: Neuroendocrine Tumors (2021-2026) & (K Units)
Figure 19. Peptide-Radionuclide Conjugates (PRCs) Consumed in Other
Figure 20. Global Peptide-Radionuclide Conjugates (PRCs) Market: Other (2021-2026) & (K Units)
Figure 21. Global Peptide-Radionuclide Conjugates (PRCs) Sale Market Share by Application (2025)
Figure 22. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application in 2026
Figure 23. Peptide-Radionuclide Conjugates (PRCs) Sales by Company in 2026 (K Units)
Figure 24. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Company in 2026
Figure 25. Peptide-Radionuclide Conjugates (PRCs) Revenue by Company in 2026 ($ millions)
Figure 26. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Company in 2026
Figure 27. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Peptide-Radionuclide Conjugates (PRCs) Sales 2021-2026 (K Units)
Figure 30. Americas Peptide-Radionuclide Conjugates (PRCs) Revenue 2021-2026 ($ millions)
Figure 31. APAC Peptide-Radionuclide Conjugates (PRCs) Sales 2021-2026 (K Units)
Figure 32. APAC Peptide-Radionuclide Conjugates (PRCs) Revenue 2021-2026 ($ millions)
Figure 33. Europe Peptide-Radionuclide Conjugates (PRCs) Sales 2021-2026 (K Units)
Figure 34. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Revenue 2021-2026 ($ millions)
Figure 37. Americas Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country in 2026
Figure 38. Americas Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Country (2021-2026)
Figure 39. Americas Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2026)
Figure 40. Americas Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021-2026)
Figure 41. United States Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Region in 2026
Figure 46. APAC Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Region (2021-2026)
Figure 47. APAC Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2026)
Figure 48. APAC Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021-2026)
Figure 49. China Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 53. India Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country in 2026
Figure 57. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Country (2021-2026)
Figure 58. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2026)
Figure 59. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021-2026)
Figure 60. Germany Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 61. France Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021-2026)
Figure 68. Egypt Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Peptide-Radionuclide Conjugates (PRCs) in 2026
Figure 74. Manufacturing Process Analysis of Peptide-Radionuclide Conjugates (PRCs)
Figure 75. Industry Chain Structure of Peptide-Radionuclide Conjugates (PRCs)
Figure 76. Channels of Distribution
Figure 77. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Forecast by Region (2027-2032)
Figure 78. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Peptide-Radionuclide Conjugates (PRCs)
Figure 2. Peptide-Radionuclide Conjugates (PRCs) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Peptide-Radionuclide Conjugates (PRCs) Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Peptide-Radionuclide Conjugates (PRCs) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country/Region (2025)
Figure 10. Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Diagnostic PRCs
Figure 12. Product Picture of Therapeutic PRCs
Figure 13. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type in 2026
Figure 14. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2021-2026)
Figure 15. Peptide-Radionuclide Conjugates (PRCs) Consumed in Prostate Cancer
Figure 16. Global Peptide-Radionuclide Conjugates (PRCs) Market: Prostate Cancer (2021-2026) & (K Units)
Figure 17. Peptide-Radionuclide Conjugates (PRCs) Consumed in Neuroendocrine Tumors
Figure 18. Global Peptide-Radionuclide Conjugates (PRCs) Market: Neuroendocrine Tumors (2021-2026) & (K Units)
Figure 19. Peptide-Radionuclide Conjugates (PRCs) Consumed in Other
Figure 20. Global Peptide-Radionuclide Conjugates (PRCs) Market: Other (2021-2026) & (K Units)
Figure 21. Global Peptide-Radionuclide Conjugates (PRCs) Sale Market Share by Application (2025)
Figure 22. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application in 2026
Figure 23. Peptide-Radionuclide Conjugates (PRCs) Sales by Company in 2026 (K Units)
Figure 24. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Company in 2026
Figure 25. Peptide-Radionuclide Conjugates (PRCs) Revenue by Company in 2026 ($ millions)
Figure 26. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Company in 2026
Figure 27. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Peptide-Radionuclide Conjugates (PRCs) Sales 2021-2026 (K Units)
Figure 30. Americas Peptide-Radionuclide Conjugates (PRCs) Revenue 2021-2026 ($ millions)
Figure 31. APAC Peptide-Radionuclide Conjugates (PRCs) Sales 2021-2026 (K Units)
Figure 32. APAC Peptide-Radionuclide Conjugates (PRCs) Revenue 2021-2026 ($ millions)
Figure 33. Europe Peptide-Radionuclide Conjugates (PRCs) Sales 2021-2026 (K Units)
Figure 34. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Revenue 2021-2026 ($ millions)
Figure 37. Americas Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country in 2026
Figure 38. Americas Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Country (2021-2026)
Figure 39. Americas Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2026)
Figure 40. Americas Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021-2026)
Figure 41. United States Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Region in 2026
Figure 46. APAC Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Region (2021-2026)
Figure 47. APAC Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2026)
Figure 48. APAC Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021-2026)
Figure 49. China Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 53. India Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country in 2026
Figure 57. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Country (2021-2026)
Figure 58. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2026)
Figure 59. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021-2026)
Figure 60. Germany Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 61. France Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021-2026)
Figure 68. Egypt Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Peptide-Radionuclide Conjugates (PRCs) Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Peptide-Radionuclide Conjugates (PRCs) in 2026
Figure 74. Manufacturing Process Analysis of Peptide-Radionuclide Conjugates (PRCs)
Figure 75. Industry Chain Structure of Peptide-Radionuclide Conjugates (PRCs)
Figure 76. Channels of Distribution
Figure 77. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Forecast by Region (2027-2032)
Figure 78. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share Forecast by Application (2027-2032)
